


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-49 are cancelled.

50. (Original) A drug-oligomer conjugate having the following general formula:



wherein

D is insulin or a functional equivalent thereof;

H is a PEG polymer having from 1 to 10 PEG units;

H' is a hydrophilic moiety;

L is a lipophilic moiety;

the H-H' bond is hydrolyzable;

q is a number from 1 to the maximum number of covalent bonding sites at which H' can form a bond with H;

o is a number from 1 to the maximum number of covalent bonding sites at which L can form a bond with H'; and

p is a number from 1 to the maximum number of covalent bonding sites at which $-(H-H')-L_o$ can form a bond with D.

51. (Original) The drug-oligomer conjugate of Claim 50, wherein H, H' and L are selected and arranged such that the drug-oligomer conjugate is amphiphilic.

52. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having from 2 to 8 PEG units.

53. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having from 2 to 7 PEG units.

54. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 3 PEG units.

55. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 4 PEG units.

56. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 5 PEG units.

57. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 6 PEG units.

58. (Original) The drug-oligomer conjugate of Claim 50, wherein H' is a hydrophilic moiety selected from the group consisting of straight or branched PEG polymers and sugars.

59. (Original) The drug-oligomer conjugate of Claim 50, wherein H' is a straight PEG polymer.

60. (Original) The drug-oligomer conjugate of Claim 59, wherein the PEG polymer has from 1 to 130 PEG units.

61. (Original) The drug-oligomer conjugate of Claim 59, wherein the PEG polymer has from 1 to 100 PEG units.

62. (Original) The drug-oligomer conjugate of Claim 50, wherein L is a lipophilic moiety selected from the group consisting of alkyl moieties, cholesterol, and fatty acid moieties.

63. (Original) The drug-oligomer conjugate of Claim 50, wherein L is an alkyl moiety.

64. (Original) The drug-oligomer conjugate of Claim 50, wherein L is cholesterol.

65. (Original) The drug-oligomer conjugate of Claim 50, wherein L is a fatty acid moiety.

66. (Original) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 2 and 28 carbon atoms.

67. (Original) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 12 and 22 carbon atoms.
68. (Original) The drug-oligomer conjugate of Claim 50, wherein D is insulin or insulin lispro.
69. (Original) The drug-oligomer conjugate of Claim 50, wherein the H'-L bond is non-hydrolyzable.
70. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $\text{CH}_3(\text{CH}_2)_n(\text{OC}_2\text{H}_4)_m\text{OH}$ (Formula 3), wherein $n = 3$ to 25 and $m = 1$ to 7.
71. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $\text{CH}_3(\text{CH}_2)_n(\text{OC}_2\text{H}_4)_m\text{OCH}_2\text{CO}_2\text{H}$ (Formula 4), wherein $n = 3$ to 25 and $m = 1$ to 6.
72. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $\text{R}-(\text{OC}_2\text{H}_4)_m\text{CH}_2\text{CO}_2\text{H}$ (Formula 6), wherein $m = 0$ to 5 and $\text{R} = \text{cholesterol or adamantine}$
73. Cancelled.
74. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $\text{CH}_3(\text{CH}_2-\text{CH}=\text{CH})_6(\text{CH}_2)_2\text{CH}_2(\text{OC}_2\text{H}_4)_m\text{OH}$ (Formula 8), wherein $m = 1$ to 7.
75. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $\text{CH}_3(\text{CH}_2-\text{CH}=\text{CH})_6(\text{CH}_2)_2\text{CX}(\text{OC}_2\text{H}_4)_m\text{OH}$ (Formula 9), wherein $m = 1$ to 7.